CHOLECALCIFEROL
本记录确认了用于欧盟化妆品标签标示的官方通用成分名称。它本身并不能确认该物质获准使用、不受限制或安全。
全球证据概览
所解析的身份在 13 个已索引市场数据集中的 7 个有匹配的监管证据:7 条国家记录和 0 条欧盟附件记录。下方列出每项结果和证据缺口。
已解析的物质身份
8 个匹配或报告的名称
全部 13 个市场的监管证据
打开每条匹配记录,查看其范围、浓度、条件、警示语和官方来源版本。
滑动或横向滚动以查看数据集覆盖范围和后续操作。
| 市场 | 结果 | 记录 | 数据集 | 含义 / 后续操作 |
|---|---|---|---|---|
| European Union EU | 未找到匹配项 | 0 | Complete annex dataset Regulation (EC) 1223/2009 consolidated to 1 May 2026 | No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review. |
| Great Britain GB | Prohibited | 1打开记录 1 | Complete consolidated annex dataset GB retained Regulation 1223/2009 schedules, effective 15 August 2026 | 请查看每条关联记录及其确切条件。 |
| Canada CA | Restricted | 1打开记录 1 | Complete Hotlist snapshot Health Canada Cosmetic Ingredient Hotlist, 13 August 2025 | 请查看每条关联记录及其确切条件。 |
| New Zealand NZ | Prohibited | 1打开记录 1 | Complete schedules dataset Cosmetic Products Group Standard schedules effective 1 January 2026 | 请查看每条关联记录及其确切条件。 |
| ASEAN ASEAN | 未找到匹配项 | 0 | Complete regional annex dataset ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026 | Regional annex coverage does not replace member-state implementation dates, notifications or national deviations. |
| China CN | Prohibited | 1打开记录 1 | Complete prohibited catalogues plus official-source workflow NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025 | 请查看每条关联记录及其确切条件。 |
| Japan JP | 未找到匹配项 | 0 | Complete Standards appendices dataset MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot | The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion. |
| South Korea KR | 未找到匹配项 | 0 | Complete current appendix dataset MFDS Notice 2026-19, effective 18 March 2026 | Korean source wording is canonical and other positive lists/notices may still apply to the formulation. |
| United States US | 未找到匹配项 | 0 | Complete enumerated federal ingredient rules eCFR Title 21 issue date 27 August 2026 | FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety. |
| Australia AU | 未找到匹配项 | 0 | Complete cosmetic-relevant Poisons Standard subset plus official workflow Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 | An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction. |
| Brazil BR | Prohibited | 1打开记录 1 | Complete prohibited dataset plus current restricted-list workflow ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026 | 请查看每条关联记录及其确切条件。 |
| India IN | Prohibited | 1打开记录 1 | Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4 Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022) | 请查看每条关联记录及其确切条件。 |
| Saudi Arabia SA | Prohibited | 1打开记录 1 | Complete official list index SFDA live prohibited/restricted lists, snapshot 30 August 2026 | 请查看每条关联记录及其确切条件。 |
匹配的市场记录和条件
Canada
Health Canada Cosmetic Ingredient Hotlist, 13 August 2025New Zealand
Cosmetic Products Group Standard schedules effective 1 January 2026China
NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025Brazil
ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026India
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)Saudi Arabia
SFDA live prohibited/restricted lists, snapshot 30 August 2026化学身份与性质

Vitamin D3
Calciol is a hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone. It has a role as a geroprotector and a human metabolite. It is a steroid hormone, a secondary alcohol, a seco-cholestane, a hydroxy seco-steroid and a member of D3 vitamins. — ChEBI
- IUPAC 名称
- (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
- 分子式
- C27H44O
- 分子量
- 384.6 g/mol
- 精确质量
- 384.339216023 Da
- XLogP3
- 7.9
- 拓扑极性表面积
- 20.2 Ų
- 氢键供体
- 1
- 氢键受体
- 1
- 共价单元
- 1
- 已定义的立体中心
- 5
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:28940
- ChEMBL:CHEMBL1042
- EPA DTXSID:DTXSID6026294
- PubMed:40633737
- PubMed:39671242
- PubMed:38588969
- PubMed:38191086
- PubMed:38081571
- PubMed:37244046
- PubMed:36813254
- PubMed:36745886
- PubMed:36603807
- PubMed:36066700
- PubMed:35395231
- PubMed:34051273
于 2026-09-02 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。
官方来源与范围
导入自委员会实施决定 (EU) 2025/1175(数据集版本 EU 2025/1175)。词汇表为第 19(1)(g) 条所要求的成分表提供通用成分名称;它不是准许清单或安全清单。
打开官方决定